bob@bobseeversconsulting.com<\/a><\/p>\n\n\n\nPhone:<\/strong> 317-417-4771<\/p>\n","protected":false},"excerpt":{"rendered":"Bob Seevers, former FDA reviewer, provides regulatory expertise in working with FDA, submissions, large and small molecules, cold chain, Quality, training, and Due Diligence. Bob worked for a decade and a half in nuclear medicine, eight years at FDA as a chemistry reviewer and team leader in several divisions, sixteen years at Eli Lilly in […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_coblocks_attr":"","_coblocks_dimensions":"","_coblocks_responsive_height":"","_coblocks_accordion_ie_support":"","footnotes":""},"class_list":["post-22","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/bobseeversconsulting.com\/index.php?rest_route=\/wp\/v2\/pages\/22","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bobseeversconsulting.com\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/bobseeversconsulting.com\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/bobseeversconsulting.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/bobseeversconsulting.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=22"}],"version-history":[{"count":11,"href":"https:\/\/bobseeversconsulting.com\/index.php?rest_route=\/wp\/v2\/pages\/22\/revisions"}],"predecessor-version":[{"id":107,"href":"https:\/\/bobseeversconsulting.com\/index.php?rest_route=\/wp\/v2\/pages\/22\/revisions\/107"}],"wp:attachment":[{"href":"https:\/\/bobseeversconsulting.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=22"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
![\"\"](\"https:\/\/bobseeversconsulting.com\/wp-content\/uploads\/2021\/10\/bob-seevers-image.jpeg\")
Bob Seevers, former FDA reviewer, provides regulatory expertise in working with FDA, submissions, large and small molecules, cold chain, Quality, training, and Due Diligence. Bob worked for a decade and a half in nuclear medicine, eight years at FDA as a chemistry reviewer and team leader in several divisions, sixteen years at Eli Lilly in Regulatory and Quality, and has worked for four years as a consultant with Pearl Pathways. <\/p>\n\n\n\n